Beyond Cost Control: Emily Gallo’s Blueprint for Supply Chain Resilience

In Part 2 of Pharmaceutical Commerce’s video interview with Emily Gallo, senior vice president and general manager of OptiFreight® Logistics at Cardinal Health, the conversation turns from high-level strategy to the operational realities of disruption, and what separates reactive supply chains from resilient ones. As pharmaceutical logistics networks grow more complex, many organizations still operate with fragmented visibility, creating blind spots that only become apparent when something goes wrong. Gallo makes the case that without a comprehensive, real-time view across inbound and outbound shipments, even well-intentioned “managed” programs can fall short when stress-tested.

That lack of end-to-end visibility becomes especially problematic in moments of disruption, whether driven by extreme weather, geopolitical shifts, or policy changes like tariffs. According to Gallo, organizations that already have predictive dashboards and integrated data in place are better positioned not just to respond to events, but to prioritize effectively—focusing on the few actions that can make an immediate impact rather than scrambling across dozens of variables. This shift from reactive firefighting to targeted, data-driven decision-making is emerging as a defining capability in modern pharma supply chains.

The discussion also drills into the financial side of the equation, unpacking where large-scale savings in logistics programs actually come from. Rather than a single lever, Gallo points to a combination of factors: smarter mode selection that avoids unnecessary premium shipping, greater consolidation of shipments within managed programs, and reducing the costly inefficiencies that arise from fragmented, off-contract freight. Just as critical, however, is cost avoidance—minimizing spoilage, delays, and performance failures that can ripple downstream to both financial losses and patient impact.

Together, these insights highlight a broader theme: in today’s environment, biopharma supply chain performance is no longer just about cost control—it’s about visibility, coordination, and the ability to act decisively when conditions change.

Access the first part of her video interview with PC:

1. How Can Predictive Analytics Transform the Pharma Supply Chain?